Summary

The stroke diagnostics market in Europe is undergoing a transformative phase, driven by rapid technological evolution, increased disease awareness, and a shift toward preventive healthcare solutions. Innovations in imaging technologies, artificial intelligence (AI), and non-invasive diagnostic tools are reshaping how strokes are identified and treated across the region.

Projections indicate a robust growth path, with the market expected to reach US$ 1.08 Bn in 2025 and further expand to US$ 1.72 Bn by 2032. This translates into a healthy compound annual growth rate (CAGR) of 6.79% from 2024 to 2032.

Market Insights

The growing prevalence of stroke-related conditions in Europe has spurred a rising demand for fast, accurate, and accessible diagnostic solutions. Advanced imaging systems—such as high-resolution CT and MRI—have become fundamental tools for stroke detection. The integration of AI into these diagnostic platforms enables clinicians to analyze data faster and more precisely, significantly improving treatment planning and outcomes.

Germany continues to lead the regional market, supported by a strong healthcare system, proactive investments in R&D, and a highly favorable regulatory environment. These factors, coupled with increasing public and institutional awareness, are enabling faster adoption of next-generation stroke diagnostic technologies.

Key Market Drivers

Several elements are propelling the growth of the stroke diagnostics market across Europe:

1. Technological Advancements: The rise of AI-powered imaging systems has transformed stroke diagnostics by providing clinicians with real-time insights and early alerts. Innovations in CT scan and MRI technologies are also reducing scan times, enhancing image quality, and minimizing radiation exposure, leading to improved patient experiences.

2. Digital Health Integration: Europe is seeing a surge in digital healthcare solutions, including telemedicine platforms and automated diagnostic systems. These tools facilitate remote consultations and streamlined diagnostic workflows, especially valuable in emergency scenarios and underserved areas.

3. Rise in Health Tech Startups: The market has welcomed several startups developing novel solutions for early stroke detection. One such example is “Time is Brain,” a Spanish startup that introduced a portable, non-invasive diagnostic device, BraiN20®, that monitors brain function in real time using tablet-based systems and disposable electrodes.

4. Supportive Government Initiatives: Public institutions are increasingly supporting stroke diagnostics innovation through grants and partnerships. In 2024, the UK and Switzerland announced collaborative funding of over £7.8 million and CHF 9.1 million, respectively, for projects targeting healthcare advancements, including AI-powered stroke diagnostic tools.

Business Opportunities

Emerging trends present lucrative avenues for stakeholders in the Europe stroke diagnostics space:

• Wearable Devices: The development of wearable tech for continuous monitoring of stroke risk is gaining momentum. These tools can identify warning signs before symptoms appear, enabling timely medical intervention.

• Non-Invasive Rapid Testing: Efforts like the GHoST (Golden HOur for STroke) project in the UK are pioneering faster and non-invasive diagnostics that could be integrated into emergency medical services, significantly cutting time-to-treatment.

• Expansion into Underserved Regions: There is a growing opportunity to deliver advanced diagnostic technologies to developing European countries with limited stroke care infrastructure. Companies expanding into these markets can improve healthcare outcomes while establishing strong regional footholds.

Regional Outlook

Germany remains at the forefront of Europe’s stroke diagnostics market. Its continued leadership is attributed to advanced infrastructure, extensive clinical research, and widespread adoption of imaging and AI technologies. The country’s academic and healthcare institutions also play a key role in fostering innovation.

The United Kingdom is emerging as another major hub, bolstered by cross-border collaborations and funding in R&D. Countries such as France, Italy, and Spain are enhancing their healthcare frameworks and adopting digital tools, driving steady market penetration. Eastern European nations, while still developing in terms of infrastructure, are showing increasing interest in affordable and scalable diagnostic technologies.

Challenges Affecting Market Growth

Despite the market's promising outlook, certain challenges must be addressed:

• Technology Integration Barriers: Existing legacy systems in many healthcare institutions are incompatible with modern diagnostic tools, necessitating costly upgrades and custom solutions. These challenges may delay implementation and adoption across certain regions.

• Variability in Diagnostic Protocols: A lack of uniform standards across different healthcare systems in Europe leads to inconsistencies in diagnosis and treatment. Harmonizing protocols is essential for ensuring standardized and efficient stroke care.

Competitive Analysis

The competitive environment in Europe’s stroke diagnostics market includes both global corporations and emerging niche players. Industry leaders such as Siemens Healthineers, GE Healthcare, and Koninklijke Philips N.V. are at the forefront, investing heavily in R&D and integrating AI into their imaging systems.

Meanwhile, companies like Brainomix are innovating with specialized tools such as the e-Stroke platform, which uses AI for enhanced stroke imaging analysis. Strategic partnerships, product launches, and cross-border collaborations are becoming common, helping companies strengthen their presence and broaden their technological offerings.

Recent Developments

• In February 2024, UC Davis Health adopted Viz.ai, an AI-based stroke diagnostic platform that rapidly analyzes CT scans and alerts care teams of potential strokes.

• In October 2023, Philips entered a two-year partnership with the World Stroke Organization to improve stroke care and prevention worldwide.

• Brainomix received FDA certification in January 2024 for its Brainomix 360 Triage Stroke tool, which identifies large vessel occlusions (LVO) and intracranial hemorrhages using non-contrast CT scans.

• The e-Stroke platform by Brainomix was deployed in November 2023 across Integrated Stroke Delivery Networks in the East of England to support better patient outcomes.

Europe Stroke Diagnostics Market Segmentation

By Stroke Type

• Ischemic Stroke

• Hemorrhagic Stroke

• Transient Ischemic Attack

By Diagnostic Test

• CT Scan

• MRI

• Carotid Ultrasound

• Cerebral Angiography

• Echocardiogram

• Others

By End User

• Hospitals

• Diagnostic Imaging Centers

• Specialty Clinics

• Ambulatory Surgical Centers

• Others

By Country

• Germany

• France

• United Kingdom

• Italy

• Spain

• Russia

• Rest of Europe

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Europe Stroke Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Country Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Europe Stroke Diagnostics Market Outlook, 2019-2032
3.1. Europe Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Hemorrhagic Stroke
3.1.1.2. Ischemic Stroke
3.1.1.3. Transient Ischemic Stroke
3.2. Europe Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Magnetic Resonance Imaging (MRI)
3.2.1.2. Computed Tomography (CT) scan
3.2.1.3. Positron Emission Tomography (PET)
3.2.1.4. Echocardiogram
3.2.1.5. Carotid Ultrasound
3.2.1.6. Cerebral Angiography
3.2.1.7. Others
3.3. Europe Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospital
3.3.1.2. Diagnostic Imaging Centers
3.3.1.3. Ambulatory Surgical Centers
3.3.1.4. Academic & Research Institutes
3.3.1.5. Others
3.4. Europe Stroke Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Germany
3.4.1.2. U.K.
3.4.1.3. France
3.4.1.4. Italy
3.4.1.5. Turkey
3.4.1.6. Russia
3.4.1.7. Rest of Europe
4. Germany Stroke Diagnostics Market Outlook, 2019-2032
4.1. Germany Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Hemorrhagic Stroke
4.1.1.2. Ischemic Stroke
4.1.1.3. Transient Ischemic Stroke
4.2. Germany Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Magnetic Resonance Imaging (MRI)
4.2.1.2. Computed Tomography (CT) scan
4.2.1.3. Positron Emission Tomography (PET)
4.2.1.4. Echocardiogram
4.2.1.5. Carotid Ultrasound
4.2.1.6. Cerebral Angiography
4.2.1.7. Others
4.3. Germany Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospital
4.3.1.2. Diagnostic Imaging Centers
4.3.1.3. Ambulatory Surgical Centers
4.3.1.4. Academic & Research Institutes
4.3.1.5. Others
5. U.K. Stroke Diagnostics Market Outlook, 2019-2032
5.1. U.K. Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Hemorrhagic Stroke
5.1.1.2. Ischemic Stroke
5.1.1.3. Transient Ischemic Stroke
5.2. U.K. Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Magnetic Resonance Imaging (MRI)
5.2.1.2. Computed Tomography (CT) scan
5.2.1.3. Positron Emission Tomography (PET)
5.2.1.4. Echocardiogram
5.2.1.5. Carotid Ultrasound
5.2.1.6. Cerebral Angiography
5.2.1.7. Others
5.3. U.K. Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospital
5.3.1.2. Diagnostic Imaging Centers
5.3.1.3. Ambulatory Surgical Centers
5.3.1.4. Academic & Research Institutes
5.3.1.5. Others
6. France Stroke Diagnostics Market Outlook, 2019-2032
6.1. France Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Hemorrhagic Stroke
6.1.1.2. Ischemic Stroke
6.1.1.3. Transient Ischemic Stroke
6.2. France Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Magnetic Resonance Imaging (MRI)
6.2.1.2. Computed Tomography (CT) scan
6.2.1.3. Positron Emission Tomography (PET)
6.2.1.4. Echocardiogram
6.2.1.5. Carotid Ultrasound
6.2.1.6. Cerebral Angiography
6.2.1.7. Others
6.3. France Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospital
6.3.1.2. Diagnostic Imaging Centers
6.3.1.3. Ambulatory Surgical Centers
6.3.1.4. Academic & Research Institutes
6.3.1.5. Others
7. Italy Stroke Diagnostics Market Outlook, 2019-2032
7.1. Italy Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Hemorrhagic Stroke
7.1.1.2. Ischemic Stroke
7.1.1.3. Transient Ischemic Stroke
7.2. Italy Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Magnetic Resonance Imaging (MRI)
7.2.1.2. Computed Tomography (CT) scan
7.2.1.3. Positron Emission Tomography (PET)
7.2.1.4. Echocardiogram
7.2.1.5. Carotid Ultrasound
7.2.1.6. Cerebral Angiography
7.2.1.7. Others
7.3. Italy Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospital
7.3.1.2. Diagnostic Imaging Centers
7.3.1.3. Ambulatory Surgical Centers
7.3.1.4. Academic & Research Institutes
7.3.1.5. Others
8. Turkey Stroke Diagnostics Market Outlook, 2019-2032
8.1. Turkey Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Hemorrhagic Stroke
8.1.1.2. Ischemic Stroke
8.1.1.3. Transient Ischemic Stroke
8.2. Turkey Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Magnetic Resonance Imaging (MRI)
8.2.1.2. Computed Tomography (CT) scan
8.2.1.3. Positron Emission Tomography (PET)
8.2.1.4. Echocardiogram
8.2.1.5. Carotid Ultrasound
8.2.1.6. Cerebral Angiography
8.2.1.7. Others
8.3. Turkey Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospital
8.3.1.2. Diagnostic Imaging Centers
8.3.1.3. Ambulatory Surgical Centers
8.3.1.4. Academic & Research Institutes
8.3.1.5. Others
9. Russia Stroke Diagnostics Market Outlook, 2019-2032
9.1. Russia Stroke Diagnostics Market Outlook, by Stroke Type, Value (US$ Bn), 2019-2032
9.1.1. Key Highlights
9.1.1.1. Hemorrhagic Stroke
9.1.1.2. Ischemic Stroke
9.1.1.3. Transient Ischemic Stroke
9.2. Russia Stroke Diagnostics Market Outlook, by Diagnostic Test, Value (US$ Bn), 2019-2032
9.2.1. Key Highlights
9.2.1.1. Magnetic Resonance Imaging (MRI)
9.2.1.2. Computed Tomography (CT) scan
9.2.1.3. Positron Emission Tomography (PET)
9.2.1.4. Echocardiogram
9.2.1.5. Carotid Ultrasound
9.2.1.6. Cerebral Angiography
9.2.1.7. Others
9.3. Russia Stroke Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032
9.3.1. Key Highlights
9.3.1.1. Hospital
9.3.1.2. Diagnostic Imaging Centers
9.3.1.3. Ambulatory Surgical Centers
9.3.1.4. Academic & Research Institutes
9.3.1.5. Others
10. Competitive Landscape
10.1. Company Market Share Analysis, 2025
10.2. Competitive Dashboard
10.3. Company Profiles
10.3.1. Siemens Healthineers AG
10.3.1.1. Company Overview
10.3.1.2. Product Portfolio
10.3.1.3. Financial Overview
10.3.1.4. Business Strategies and Development
10.3.2. Koninklijke Philips N.V.
10.3.2.1. Company Overview
10.3.2.2. Product Portfolio
10.3.2.3. Financial Overview
10.3.2.4. Business Strategies and Development
10.3.3. Esaote S.p.A
10.3.3.1. Company Overview
10.3.3.2. Product Portfolio
10.3.3.3. Financial Overview
10.3.3.4. Business Strategies and Development
10.3.4. FUJIFILM
10.3.4.1. Company Overview
10.3.4.2. Product Portfolio
10.3.4.3. Financial Overview
10.3.4.4. Business Strategies and Development
10.3.5. Medtronic
10.3.5.1. Company Overview
10.3.5.2. Product Portfolio
10.3.5.3. Financial Overview
10.3.5.4. Business Strategies and Development
10.3.6. Canon Medical Systems Corporation
10.3.6.1. Company Overview
10.3.6.2. Product Portfolio
10.3.6.3. Financial Overview
10.3.6.4. Business Strategies and Development
10.3.7. GE Healthcare
10.3.7.1. Company Overview
10.3.7.2. Product Portfolio
10.3.7.3. Financial Overview
10.3.7.4. Business Strategies and Development
10.3.8. Samsung
10.3.8.1. Company Overview
10.3.8.2. Product Portfolio
10.3.8.3. Financial Overview
10.3.8.4. Business Strategies and Development
10.3.9. CURVEBEAMAI
10.3.9.1. Company Overview
10.3.9.2. Product Portfolio
10.3.9.3. Financial Overview
10.3.9.4. Business Strategies and Development
10.3.10. Carestream Health
10.3.10.1. Company Overview
10.3.10.2. Product Portfolio
10.3.10.3. Financial Overview
10.3.10.4. Business Strategies and Development
10.3.11. Planmed Oy
10.3.11.1. Company Overview
10.3.11.2. Product Portfolio
10.3.11.3. Financial Overview
10.3.11.4. Business Strategies and Development
11. Appendix
11.1. Research Methodology
11.2. Report Assumptions
11.3. Acronyms and Abbreviations